Updates from Syncona and our portfolio companies
Syncona speaks to one of Quell Therapeutics’ academic founders, Alberto Sanchez-Fueyo, about his career, the potential of T-regulatory cells and his vision for the business.
Emma Salisbury, mother of Tommy Salisbury, tells us about the impact of Choroideremia and the potential of gene therapy.
Syncona speaks to Achilles Therapeutics' clinical founder Charlie Swanton about his career, the advent of immunotherapy, and what he wants Achilles to achieve.
Patients on Nightstar's clinical trial tell us about their experience with the diseases which causes blindness in males, and their hopes for Nightstar's potential treatment.